Navigation Links
Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds
Date:6/28/2010

A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half approximately 49 percent completed their full regimen of hormone therapy according to the prescribed schedule. Investigators found that younger women were particularly likely to discontinue treatment. The findings underscore the need to both better understand the reasons behind such treatment non-compliance and also develop interventions to reduce it.

"We were surprised to see that so many young women stopped treatment early, despite the fact that the therapy has a proven track record of reducing breast cancer recurrence," said Dawn Hershman, MD, associate professor of medicine and epidemiology at Columbia University Medical Center, who led the study. "Perhaps we need to do a better job of making patients aware that to get the full benefit of treatment, they need to take their medications on time and for the full duration."

While up to five years of oral hormone therapy (such as tamoxifen and aromatase inhibitors) for hormone-sensitive breast cancers is frequently prescribed to reduce the risk of cancer recurrence and death, some previous small studies indicated that only approximately 40 to 60 percent of women finish their recommended course of therapy. In order to provide a more comprehensive perspective, Dr. Hershman and her colleagues examined automated pharmacy records of 8,769 women diagnosed with stage I, II or III, hormone-sensitive breast cancer between 1996 and 2007. They used the records to identify hormonal therapy prescriptions and refill dates. Each woman filled at least one prescription for hormonal therapy within one year of diagnosis. Women used tamoxifen (43 percent), aromatase inhibitors (26 percent) or both (30 percent).

The researchers found that women under age 40 had the highest risk of discontinuing therapy early. By 4.5 years, 32 percent of all patients in the study had stopped taking their hormone therapy, and of those who did not stop, only 72 percent finished on schedule (meaning they took their medication more than 80 percent of the time).

They found that in women younger than 40 and older than 75, those who had lumpectomy as opposed to mastectomy and those with other medical illnesses were more likely to discontinue hormonal therapy early. Asian/Pacific Islander ethnicity, a history of prior chemotherapy, being married and longer prescription refill intervals were associated with completing 4.5 years of hormonal therapy. Longer refill intervals meant fewer chances to not refill prescriptions.

"Physicians are often unaware of patient compliance, and this is becoming an increasingly important issue in cancer," Dr. Hershman said. "It's very disturbing that patients under 40 had the highest discontinuation and non-adherence rates, because those patients have the longest life expectancy. If we can better understand the issues surrounding compliance with hormonal therapy, this might help us understand why patients don't adhere to other treatments that are moving out of the clinic and into the home, such as oral chemotherapy, as often as we would like."

She added that there are several possible reasons for halting therapy early, noting that 13 percent of the women delayed getting their first prescription refilled. These factors can include the side effects of the therapy, such as joint pain, hot flashes or fatigue, a lack of understanding of the benefit of the therapy, and high costs of medications and/or insurance co-payments.

ASCO Perspective

Jennifer Obel, MD, member of ASCO's Cancer Communications Committee

"This new study reaffirms some worrisome trends for women completing hormonal therapy, and brings up the larger issue of non-compliance for cancer therapies in general. As we increasingly move treatments out of the clinic and into the home we now have more than 50 oral chemotherapy medications compliance has become a significant problem that hasn't been addressed very well. Patients tend to underestimate side effects and under-report events that happen between clinic visits. We need to identify reasons why patients don't take their drugs before we can find ways to reverse this trend."


'/>"/>

Contact: Elizabeth Streich
eas2125@columbia.edu
212-305-6535
Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Fewer Childhood Deaths From Rheumatic Disease
2. Improved air quality linked to fewer pediatric ear infections
3. Even a Small Dietary Reduction in Salt Could Mean Fewer Heart Attacks, Strokes and Deaths
4. HIV Therapy Linked to Fewer Suicides
5. Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis
6. Fewer left-sided colorectal tumors observed after colonoscopies
7. Fewer headaches on the horizon thanks to latest guidelines
8. Recession May Mean Fewer Nips & Tucks
9. Fewer platelets could be used for some cancer and bone-marrow transplantation patients
10. Fewer Deaths in Larger, Busier Hospitals
11. Pitt/Magee research finds women with preeclampsia have fewer blood vessel precursor cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Early this week, Team Iconic at J. Walter Thompson ... as the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé ... their product, through activities that focus on better farming, better lives and better cocoa. ...
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency ... find. Unfortunately, this can leave patients with dental emergencies at risk of losing a ... offering emergency dental care. , Common dental emergencies include:, , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... biopharmaceutical company developing novel, clinical-stage therapies for sickle cell ... an underwritten public offering of 29,090,910 units at a ... unit consists of one share of the Company,s common ... the Company,s common stock at an exercise price of ...
(Date:2/10/2016)... , Feb. 10, 2016 /PRNewswire/ - The President ... has announced the release of an anti-radiation product ... a revolutionary breakthrough in the treatment of cancer ... exposure. It will assist in the healing of ... It will also protect only the healthy cells ...
Breaking Medicine Technology: